MPDL3280A

DRUG12 trials

Sponsors

University College, London, University of Michigan Rogel Cancer Center, University Medical Center Groningen, Yale University, M.D. Anderson Cancer Center

Conditions

Anal CancerBladder CancerCarcinoma, Non-Small-Cell LungInvasive Ductal Breast CarcinomaLocally Advanced or Metastatic Solid TumorsLung CancerNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Early Phase 1

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

CompletedNCT02463994

University of Michigan Rogel Cancer CenterNon-small Cell Lung Cancer

Start: 2015-10-31End: 2018-11-07Updated: 2019-02-08

Phase 1

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

TerminatedNCT02630186

Clovis Oncology, Inc.Non-small Cell Lung Cancer

Start: 2016-02-24End: 2017-09-05Updated: 2019-07-05

Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer

TerminatedNCT02748889

Giuseppe GiacconeSmall Cell Lung Cancer ( SCLC )

Start: 2016-03-31End: 2017-05-09Updated: 2018-07-02

Phase 2

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Active, not recruitingNCT02314481

University College, LondonNon-small Cell Lung Cancer

Start: 2017-05-12End: 2026-05-31Updated: 2025-05-23

MPDL3280A-treatment-IST-UMCG

Active, not recruitingNCT02478099

University Medical Center GroningenLocally Advanced or Metastatic Solid Tumors

Start: 2016-02-24End: 2024-07-31Updated: 2024-05-03

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

WithdrawnNCT02495636

Yale UniversityNon-Small Cell Lung Cancer

Start: 2015-07-31End: 2017-07-31Updated: 2017-06-22

MPDL3280A With Chemoradiation for Lung Cancer

Active, not recruitingNCT02525757

M.D. Anderson Cancer CenterLung Cancer, Non-Small Cell Lung Cancer

Start: 2016-01-26End: 2028-01-31Updated: 2026-02-04

Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder

CompletedNCT02662309

Queen Mary University of LondonBladder Cancer

Start: 2016-02-01End: 2020-06-11Updated: 2025-03-10

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

CompletedNCT02716038

Columbia UniversityCarcinoma, Non-Small-Cell Lung

Start: 2016-06-07End: 2022-10-01Updated: 2023-12-12

A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

CompletedNCT03519295

GERCOR - Multidisciplinary Oncology Cooperative GroupAnal Cancer

Start: 2018-07-03End: 2023-09-20Updated: 2025-06-27

AN EARLY PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS

Active, not recruitingNL-OMON47877

F. Hoffmann-La Roche Ltd.Solide tumors and lymphoma's

Start: 2016-01-21Target: 2Updated: 2024-02-28

Phase 3

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

CompletedNCT02620280

Fondazione MichelangeloInvasive Ductal Breast Carcinoma

Start: 2016-04-30End: 2024-01-07Updated: 2024-03-06

Related Papers

Analysis of event-free survival (EFS) of stromal tumor infiltrating lymphocytes (sTILs), PD-L1 expression, and their early dynamics in the NeoTRIP trial.

Journal of Clinical Oncology2025-05-28

Tumor-specific MHC class II upregulation associated with response to anti-PD-L1 therapy in patients with urothelial cancer.

Journal of Clinical Oncology2024-06-01

Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer

Nature Communications2024-05-2424 citations

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.

2024-04-0113 citations

Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

Journal of Clinical Oncology2024-01-295 citations

Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders

Journal for ImmunoTherapy of Cancer2024-01-0110 citations

Whole-body CD8<sup>+</sup> T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.

2022-12-0588 citations

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

Frontiers in Oncology2022-08-248 citations

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)

Frontiers in Immunology2022-06-0251 citations

Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study.

Journal of Clinical Oncology2022-06-0117 citations

Monitoring engorgement of phagocytic circulating stromal cells during chemo-radiotherapy induction predicts survival in unresectable stage 2/3 NSCLC.

Journal of Clinical Oncology2022-06-01

Insights on ctDNA-Guided Adjuvant Immunotherapy in Urothelial Carcinoma

Oncology Times2021-11-03

Abstract LB037: 89ZED88082A PET imaging to visualize CD8+ T cells in patients with cancer treated with immune checkpoint inhibitor

Cancer Research2021-07-018 citations

Abstract SY13-03: Neoadjuvant immunotherapy for operable non-small cell lung cancer: Lessons learned and current challenges

Cancer Research2021-07-011 citations

Sequential monitoring of PD-L1 on circulating stromal cells in blood predicts PFS in NSCLC patients undergoing immunotherapy after definitive chemoradiation.

Journal of Clinical Oncology2021-05-202 citations

[Application of Neoadjuvant Immuno-chemotherapy in NSCLC].

2021-04-015 citations

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial.

2021-02-1819 citations

Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy.

2020-10-0112 citations

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.

2020-08-2616 citations

Abstract 3297: Expression of pd-l1 on circulating stromal cells predicts immunotherapy response in unresectable non-small cell lung carcinoma after definitive chemoradiotherapy

Cancer Research2020-08-15

15 more papers not shown